MX379558B - Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3-il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino)-benzamida. - Google Patents
Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3-il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino)-benzamida.Info
- Publication number
- MX379558B MX379558B MX2018014298A MX2018014298A MX379558B MX 379558 B MX379558 B MX 379558B MX 2018014298 A MX2018014298 A MX 2018014298A MX 2018014298 A MX2018014298 A MX 2018014298A MX 379558 B MX379558 B MX 379558B
- Authority
- MX
- Mexico
- Prior art keywords
- indazol
- ylamino
- piperazin
- benzamide
- pyran
- Prior art date
Links
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662340797P | 2016-05-24 | 2016-05-24 | |
| PCT/EP2017/061919 WO2017202674A1 (en) | 2016-05-24 | 2017-05-18 | New crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018014298A MX2018014298A (es) | 2019-03-14 |
| MX379558B true MX379558B (es) | 2025-03-11 |
Family
ID=58709993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014298A MX379558B (es) | 2016-05-24 | 2017-05-18 | Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3-il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino)-benzamida. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10738037B2 (enExample) |
| EP (2) | EP3464276B1 (enExample) |
| JP (2) | JP7094228B2 (enExample) |
| KR (1) | KR102441736B1 (enExample) |
| CN (1) | CN109153669B (enExample) |
| AU (1) | AU2017271458B2 (enExample) |
| CA (1) | CA3024208C (enExample) |
| ES (1) | ES2899953T3 (enExample) |
| IL (1) | IL263004B (enExample) |
| MX (1) | MX379558B (enExample) |
| PL (1) | PL3464276T3 (enExample) |
| WO (1) | WO2017202674A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7094228B2 (ja) * | 2016-05-24 | 2022-07-01 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｎ－［５－（３，５－ジフルオロ－ベンジル）－１ｈ－インダゾール－３－イル］－４－（４－メチル－ピペラジン－１－イル）－２－（テトラヒドロ－ピラン－４－イルアミノ）－ベンズアミドの新規結晶形 |
| MX2022001159A (es) | 2019-07-31 | 2022-02-22 | Hoffmann La Roche | Nueva formulacion farmaceutica. |
| US20220372024A1 (en) * | 2019-11-01 | 2022-11-24 | Johnson Matthey Public Limited Company | Crystalline forms of entrectinib |
| CN113024521B (zh) * | 2019-12-09 | 2023-01-17 | 武汉九州钰民医药科技有限公司 | 一种制备恩曲替尼的方法 |
| CN111171009B (zh) * | 2020-01-10 | 2022-07-12 | 安礼特（上海）医药科技有限公司 | 恩曲替尼晶型及其制备方法 |
| CN113354626B (zh) * | 2020-03-04 | 2025-06-03 | 罗欣药业(上海)有限公司 | 恩曲替尼的晶型及其制备方法 |
| CN113801062B (zh) * | 2020-06-15 | 2023-05-26 | 沈阳药科大学 | 3-氨基-5-(3,5-二氟苄基)-1h-吲唑的制备方法 |
| CN112336723B (zh) * | 2020-12-11 | 2023-09-26 | 江南大学 | 制备用于降低trpv4与nox2耦联度的药物的方法 |
| WO2022166647A1 (zh) | 2021-02-03 | 2022-08-11 | 齐鲁制药有限公司 | 恩曲替尼晶型及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA018503B1 (ru) | 2007-07-20 | 2013-08-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Замещенные производные индазола, активные как ингибиторы киназы |
| NZ703124A (en) * | 2012-05-23 | 2016-07-29 | Nerviano Medical Sciences Srl | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| JP7094228B2 (ja) | 2016-05-24 | 2022-07-01 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｎ－［５－（３，５－ジフルオロ－ベンジル）－１ｈ－インダゾール－３－イル］－４－（４－メチル－ピペラジン－１－イル）－２－（テトラヒドロ－ピラン－４－イルアミノ）－ベンズアミドの新規結晶形 |
-
2017
- 2017-05-18 JP JP2018561474A patent/JP7094228B2/ja active Active
- 2017-05-18 AU AU2017271458A patent/AU2017271458B2/en active Active
- 2017-05-18 US US16/301,826 patent/US10738037B2/en active Active
- 2017-05-18 ES ES17724052T patent/ES2899953T3/es active Active
- 2017-05-18 CN CN201780031576.6A patent/CN109153669B/zh active Active
- 2017-05-18 WO PCT/EP2017/061919 patent/WO2017202674A1/en not_active Ceased
- 2017-05-18 PL PL17724052T patent/PL3464276T3/pl unknown
- 2017-05-18 EP EP17724052.0A patent/EP3464276B1/en active Active
- 2017-05-18 CA CA3024208A patent/CA3024208C/en active Active
- 2017-05-18 KR KR1020187037182A patent/KR102441736B1/ko active Active
- 2017-05-18 EP EP21188238.6A patent/EP3967689A1/en not_active Withdrawn
- 2017-05-18 MX MX2018014298A patent/MX379558B/es unknown
-
2018
- 2018-11-14 IL IL263004A patent/IL263004B/en unknown
-
2020
- 2020-06-26 US US16/912,965 patent/US11091469B2/en active Active
- 2020-11-06 JP JP2020185594A patent/JP7154271B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10738037B2 (en) | 2020-08-11 |
| EP3967689A1 (en) | 2022-03-16 |
| IL263004A (en) | 2018-12-31 |
| CA3024208A1 (en) | 2017-11-30 |
| HK1259405A1 (zh) | 2019-11-29 |
| JP7154271B2 (ja) | 2022-10-17 |
| WO2017202674A1 (en) | 2017-11-30 |
| KR20190005236A (ko) | 2019-01-15 |
| BR112018073951A2 (pt) | 2019-02-26 |
| AU2017271458A1 (en) | 2019-01-17 |
| US11091469B2 (en) | 2021-08-17 |
| KR102441736B1 (ko) | 2022-09-13 |
| AU2017271458B2 (en) | 2020-11-26 |
| EP3464276B1 (en) | 2021-09-01 |
| ES2899953T3 (es) | 2022-03-15 |
| JP7094228B2 (ja) | 2022-07-01 |
| US20200325122A1 (en) | 2020-10-15 |
| MX2018014298A (es) | 2019-03-14 |
| CA3024208C (en) | 2022-07-26 |
| CN109153669B (zh) | 2021-12-24 |
| JP2021042213A (ja) | 2021-03-18 |
| CN109153669A (zh) | 2019-01-04 |
| PL3464276T3 (pl) | 2022-04-04 |
| US20190169173A1 (en) | 2019-06-06 |
| IL263004B (en) | 2022-04-01 |
| EP3464276A1 (en) | 2019-04-10 |
| JP2019516749A (ja) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ716487A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
| TN2016000268A1 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2. | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| PH12015502792A1 (en) | Crystalline bromodomain inhibitors | |
| TN2019000281A1 (en) | Ferroportin-inhibitor salts | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| GEP20207147B (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
| PH12016501439B1 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| JO3780B1 (ar) | مثبطات فيروبورتين جديدة | |
| SA515360007B1 (ar) | مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk) | |
| MX2015013481A (es) | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| PH12021550324A1 (en) | 5 to 7 membered heterocyclic amides as jak inhibitors | |
| MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
| EA201592238A1 (ru) | Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма | |
| MX2018014298A (es) | Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| WO2017134685A3 (en) | Novel hydrazino compounds as btk inhibitors | |
| MX2017014752A (es) | Nuevos etinos de amidoheteroaril aroil hidrazida. | |
| WO2017168454A3 (en) | Novel compounds as btk inhibitors | |
| MX385475B (es) | Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa |